UBS AM
ELVN icon

UBS AM’s Enliven Therapeutics ELVN Stock Holding History

UBS AM’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06M Buy
80,072
+12,597
+19% +$535K ﹤0.01% 1706
2026
Q1 		$2.65M Buy
67,475
+12,265
+22% +$340K ﹤0.01% 1906
2025
Q4 		$850K Buy
55,210
+3,527
+7% +$70.3K ﹤0.01% 2192
2025
Q3 		$1.06M Sell
51,683
-31,371
-38% -$632K ﹤0.01% 1985
2025
Q2 		$1.67M Buy
83,054
+47,156
+131% +$893K ﹤0.01% 2220
2025
Q1 		$706K Sell
35,898
-7,816
-18% -$168K ﹤0.01% 2423
2024
Q4 		$984K Buy
43,714
+17,546
+67% +$455K ﹤0.01% 2369
2024
Q3 		$668K Buy
26,168
+2,944
+13% +$68.2K ﹤0.01% 2558
2024
Q2 		$543K Buy
+23,224
New +$489K ﹤0.01% 2606

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

UBS AM's ELVN Position: Q2 2026 in Review

UBS AM increased its Enliven Therapeutics (ELVN) stake by 19% in Q2 2026, buying an estimated $535K and bringing the position to 80,072 shares worth $4.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

UBS AM first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • UBS AM held 80,072 shares of Enliven Therapeutics worth $4.06M as of Q2 2026.
  • UBS AM bought 12,597 Enliven Therapeutics shares in Q2 2026, an estimated $535K.
  • Enliven Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1706 holding.
  • UBS AM first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.